T-Regulatory Cells Archives - Page 6 of 6

Abstract Number: 1643 • ACR/ARHP Annual Meeting 2013
Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg
Gali Malul¹, David Soler², Donald D. Anthony³, Hillard M. Lazarus⁴, Nicholas Lehman⁵, Thomas McCormick², Julia M. Sugalski⁶, Anthony E. Ting⁵ and Nora G. Singer⁷, ¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²Dermatology, Case Medical Center, Cleveland, OH, ³Medicine, Case Western Reserve University, Cleveland, OH, ⁴Comprehensive Cancer Center, Case Medical Center, Cleveland, OH, ⁵Athersys, Inc., Cleveland, OH, ⁶Medicine/infectious disease, Case Western Reserve University, Cleveland, OH, ⁷Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Use of mesenchymal/multipotent stem cells (MSCs/MAPCs) is an emerging immune modulatory therapeutic strategy promising for a number of human diseases. Multipotent adult progenitor cells…
Abstract Number: 1641 • ACR/ARHP Annual Meeting 2013
Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B
Stefanie Koristka¹, Marc Cartellieri², Claudia Arndt², Anja Feldmann², Irene Michalk², Claudia C. Bippes², Nicole Berndt², Anne Hermsdorf², Slava Stamova², Biji T. Kurien³, Robert Hal Scofield⁴, A. Darise Farris⁵, Judith A. James⁶, Holger Bartsch⁷ and Michael Bachmann², ¹Carl Gustav Carus TU-Dresden, Dresden, Germany, ²Inst. Immunology, Carl Gustav Carus TU-Dresden, Dresden, Germany, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Inst. Immunol., Carl Gustav Carus TU-Dresden, Dresden, Germany
Background/Purpose: Adoptive transfer of regulatory T cells (Tregs) represents a promising strategy for treatment of auto- and alloimmunity. However, it is difficult to obtain therapeutically…
Abstract Number: 1412 • ACR/ARHP Annual Meeting 2013
Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis
Eva Dokoupilova¹, Slawomir Jeka², Jiri Vencovsky³, Janusz Badurski⁴, Klaas Prins⁵, Vibeke Strand⁶, Edward C. Keystone⁷, Ronald F van Vollenhoven⁸, Jurgen Wollenhaupt⁹, Andrea Wartenberg-Demand¹⁰, Gabriele Niemann¹⁰, Ahmed Abufarag¹⁰, Silke Aigner¹⁰, Sibylle Kaiser¹⁰, Faiza Rharbaoui¹⁰, Niklas Czeloth¹¹, Ralf Wolter¹⁰, Benjamin Dälken¹⁰ and Thorsten Holzkämper¹⁰, ¹Medical Plus s.r.o, Uherske Hradiste, Czech Republic, ²Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ³Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, ⁵qPharmetra, Nijmegen, Netherlands, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁰Biotest AG, Dreieich, Germany, ¹¹Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: In patients with rheumatoid arthritis (RA) reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed. Tregalizumab is a humanized, agonistic…
Abstract Number: 719 • ACR/ARHP Annual Meeting 2013
Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)
Hiroshi Kato¹ and Andras Perl², ¹Internal Medicine, Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: mTOR activity is increased in SLE T cells and its blockade has therapeutic efficacy in SLE. Murine studies showed essential roles of mTORC1 in…
Abstract Number: 665 • ACR/ARHP Annual Meeting 2013
DNA hypermethylation of Forkhead box protein 3 (FOXP3) locus leads to quantitative defects of regulatory T cells in systemic sclerosis
Yaoyao Wang¹, Ye Shu², Qing Wang¹, Ming Zhao¹, Gongping Liang¹, Qianjin Lu¹ and Rong Xiao¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Hunan Children's Hospital, Changsha, China

Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of which the etiology and pathogenesis remains complex and poorly understood. Attention has recently been directed…

Abstracts tagged "T-Regulatory Cells"

Ex Vivo Suppression Of RA Effector T Cells (Teff) By Mapc Media Is Synergistic With Treg

Bispecific Antibodies For Redirection Of Human Regulatory T Cells To Surface-Inducible Autoantigen La/SS-B

Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical Analysis To Inform Further Clinical Development, Including Dose Selection For The Phase 2b Trial – Treat 2b – Of Tregalizumab In Rheumatoid Arthritis

Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)

DNA hypermethylation of Forkhead box protein 3 (FOXP3) locus leads to quantitative defects of regulatory T cells in systemic sclerosis